Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.

Anderson, Peter L; Marzinke, Mark A; Glidden, David V

Anderson, Peter L; Marzinke, Mark A; Glidden, David V.

Affiliation

Anderson PL; Department of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
Marzinke MA; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Glidden DV; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Clin Infect Dis ; 76(10): 1850-1853, 2023 05 24.

Article in En | MEDLINE | ID: mdl-36645796

Subject(s)

Anti-HIV Agents; HIV Infections; Pre-Exposure Prophylaxis; Male; Humans; Female; Tenofovir/therapeutic use; Emtricitabine/therapeutic use; HIV; Medication Adherence; Reverse Transcriptase Inhibitors/therapeutic use; HIV Infections/drug therapy; HIV Infections/prevention & control; Anti-HIV Agents/therapeutic use

Key words

PrEP; adherence; pharmacology; sex differences; tenofovir

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: HIV Infections / Anti-HIV Agents / Pre-Exposure Prophylaxis Limits: Female / Humans / Male Language: En Journal: Clin Infect Dis Journal subject: DOENCAS TRANSMISSIVEIS Year: 2023 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google